Evidence map›Paper›PMID 33400014›Full record

ReviewCurrent treatment options in oncology2021

Translating Knowledge About the Immune Microenvironment of Gastrointestinal Stromal Tumors into Effective Clinical Strategies.

Jomjit Chantharasamee, Jacob J Adashek, Karlton Wong, Mark A Eckardt, Bartosz Chmielowski, Sarah Dry, Fritz C Eilber, Arun S Singh

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current treatment options in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Ferroptosis in gastrointestinal stromal tumors.Journal of gastrointestinal oncology · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Jomjit ChantharasameeDivision of Hematology-Oncology, University of California Los Angeles, Los Angeles, CA, USA.
Jacob J AdashekDepartment of Internal Medicine, University of South Florida, H. Lee Moffit Cancer Center, Tampa, FL, USA.
Karlton WongDivision of Hematology-Oncology, University of California Los Angeles, Los Angeles, CA, USA.
Mark A EckardtDepartment of Surgery, Yale School of Medicine, New Haven, CT, USA.
Bartosz ChmielowskiDivision of Hematology-Oncology, University of California Los Angeles, Los Angeles, CA, USA.
Sarah DryUCLA-JCCC Sarcoma Program, Los Angeles, CA, USA.
Fritz C EilberDivision of Surgical Oncology, University of California Los Angeles, Los Angeles, CA, USA.
Arun S SinghDivision of Hematology-Oncology, University of California Los Angeles, Los Angeles, CA, USA. asingh@mednet.ucla.edu.
University of California, Los Angeles · USMoffitt Cancer Center · USSiriraj Hospital · THYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementThe role of targeted therapy is firmly established for gastrointestinal stromal tumors (GISTs); other modalities for targeting this disease are necessary for recurrent and refractory disease. There are several lines of evidence pointing to an active role of the immune system in GIST. Preclinical and clinical studies revealed that the most common type of immune cell infiltration in GISTs is tumor-associated macrophages (TAMs). The mechanism of how TAMs sculpt the tumor microenvironment in GIST is not clear, but it seems that the presence of immunosuppressive regulatory T cells (Tregs) is correlated with the number of TAMs, thus linking macrophages to immunosuppression. CD3+ T cells and NK infiltrates are found in the GIST microenvironment and carry some prognostic value. In early clinical trials, there is evidence for an active role for immunotherapy in treating GIST patients. Moreover, preclinical evidence has indicated that combining TKIs with checkpoint blockers may be synergistic in murine GIST models. Overall, there is substantial preclinical and clinical evidence to support a role for immunoregulation in GIST and further studies will be important for the development of immunotherapies for GIST.

Indexed as

ImmunotherapyGastrointestinal Stromal TumorsHumansImatinib MesylateLymphocytes, Tumor-InfiltratingNeoplasm Recurrence, LocalT-LymphocytesTumor-Associated MacrophagesTumor MicroenvironmentImatinib MesylateCancer clinical trialsGastrointestinal stromal tumorsImmune checkpoint inhibitorsImmunotherapy

Identifiers

PMID33400014
OpenAlexW3120819348

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.